Clinical trial
Phase 2b/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Dipraglurant (ADX48621) for the Treatment of Dyskinesia in Patients With Parkinson's Disease Receiving Levodopa-based Therapy
NCT04857359 is registered in ClinicalTrials.gov with Addex Pharma S.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2b/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Dipraglurant (ADX48621) for the Treatment of Dyskinesia in Patients With Parkinson's Disease Receiving Levodopa-based Therapy
- Lead sponsor
- Addex Pharma S.A.
- Phase
- Phase 2/3
- Overall status
- Terminated
- Start date
- August 6, 2021
- Completion date
- August 15, 2022
- Enrollment
- 25 (actual)
- Sites
- 41
Conditions
As the registry lists them; a condition with its own page is linked.